this post was submitted on 06 Jan 2024
333 points (95.6% liked)
Technology
59424 readers
2939 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
Vaselgel is too cheap to manufacture to get the funding it needs to bring it to market, that's why they have been trying for 20 years and haven't succeeded yet. In the US the rights are owned by a non profit Parsemu Foundation formed to fund it. It looks like their private partner NEXT Life Sciences is actually set to come to market with a vaselgel product in 2026 they are calling Plan A.
https://www.prnewswire.com/news-releases/next-life-sciences-announces-launch-of-plan-a-birth-control-for-men-301779007.html
Interesting marketing choice comparing it to the Plan B pill.
From what I'm reading, they're not set to go to market; that's just their goal. Most recent article I found was middle of last year that they had raised more money and were hoping to go to human trials by the end of the year. That aligns with what I remember about Vasalgel from years ago - they had finally made it to monkey trials but their monkey study was not showing a consistent ability to return to virility with the second injection. I seem to remember the proposed reason being that vas deferens in the monkeys/apes they were testing with are actually more delicate than humans' and so humans should still likely be reversible. Last I heard, I believe they were trying to move forward on the human trial of proving that it works as a contraceptive, to be followed by a human trial showing reversibility. Then radio silence and funding issues. My assumption has always been that they struggled to jump to human trials because of the primate study results hurting the likelihood of reversibility. Hopefully they have reworked it to solve that, or maybe the acquisition and new funding is enough to just push through that regardless and see if humans will be fine.